1131007-43-6 Usage
Uses
Used in Chemical Synthesis:
6-(difluoroMethoxy)pyridin-2-aMine is used as an intermediate or reactant in chemical synthesis for its high reactivity, contributing to the formation of various complex organic compounds.
Used in Pharmaceutical Industry:
6-(difluoroMethoxy)pyridin-2-aMine is used as a building block in the development of pharmaceutical compounds, leveraging its unique molecular structure to create new drugs with potential therapeutic applications.
Used in Laboratory Research:
6-(difluoroMethoxy)pyridin-2-aMine is used as a research compound in laboratories to study its properties and explore its potential applications in various chemical and biological processes.
Note: The specific applications and industries may vary based on further research and development. The provided uses are general and may be expanded upon with additional studies.
Check Digit Verification of cas no
The CAS Registry Mumber 1131007-43-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,3,1,0,0 and 7 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1131007-43:
(9*1)+(8*1)+(7*3)+(6*1)+(5*0)+(4*0)+(3*7)+(2*4)+(1*3)=76
76 % 10 = 6
So 1131007-43-6 is a valid CAS Registry Number.
1131007-43-6Relevant academic research and scientific papers
KIF18A INHIBITORS
-
Paragraph 0280, (2020/07/14)
Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors
-
Paragraph 0280-0283; 0328-0331, (2018/03/01)
The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
